Please assess the completion status of the following clinical trial:

Trial Title: Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adults ≤ 70 years old~* indication to stem cells transplantation with reduced-intensity conditioning regimen~* with a HLA-compatible familial 10/10 or non-familial donor~* Written signed informed consent form~* woman with childbearing potential under efficient control birth method during the trial and up to 12 months after cyclophosphamide stop~* men under efficient control birth method during the trial and up to 6 months after cyclophosphamide stop~* Negative serology to B and C hepatitis and to HIV~* Affiliated to social security~Exclusion Criteria:~* - Eligible to myeloablative contioning regimen~* Other progressive malignancy disease or history of prior other malignancy in the last two years, with the exception of: curatively treated basal cell carcinoma or carcinoma in situ of the cervix~* Progressive mental illness disease~* Pregnant or Breastfeeding woman~* woman with childbearing potential without any efficient control birth~* Serious concomitant infection and not controlled~* Contra-indications to allogenic transplantation, especially:~  * Cardiac: left ventricular ejection fraction \<45% assessed by transthoracic echography or isotopic method (isotopic gamma-angiography)~ * Respiratory: DLCO limiting fludarabine and busulfan use (DLCO\< 40% of theorical value)~ * Renal: creatinine clearance \< 60ml/min (MDRD method)~ * Hepatic: transaminases \>5 Uper Per Normal (UPN) or bilirubin\> 2 UPN~* Contra-indications to cyclophosphamide:~  * Urinary tract infections~ * Acute urothelial toxicity due to cytotoxic chemotherapy or to radiotherapy~ * Obstruction of urines flow~ * Pre-existing hemorrhagic cystitis~ * Yellow fever vaccination~* Cardiac condition preventing high dose cyclophosphamide utilization :~  * New York Heart Association (NYHA) functional class II, III or IV~ * Rhythmic, valvular or ischemic cardiomyopathy~* Minor~* Patient under guardianship or curatorship~* Patient under judicial protection~* Known or suspected hypersensitivity to cyclophosphamide~* Known or suspected hypersensitivity to rabbit proteins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LYMPHOID HEMOPATHY without ATG (Type: EXPERIMENTAL): patients with lymphoid hemopathy
- MYELOID HEMOPATHY without ATG (Type: EXPERIMENTAL): patients with myeloid hemopathy
- LYMPHOID HEMOPATHY witH ATG (Type: EXPERIMENTAL): patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
- MYELOID HEMOPATHY with ATG (Type: EXPERIMENTAL): patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility